Journal of Chemistry

Journal of Chemistry / 2013 / Article

Research Article | Open Access

Volume 2013 |Article ID 656271 |

B. A. Baviskar, S. S. Khadabadi, S. L. Deore, "Synthesis and Evaluation of Some New Thiazolidin-4-One Derivatives as Potential Antimicrobial Agents", Journal of Chemistry, vol. 2013, Article ID 656271, 6 pages, 2013.

Synthesis and Evaluation of Some New Thiazolidin-4-One Derivatives as Potential Antimicrobial Agents

Academic Editor: Hakan Arslan
Received25 Jun 2012
Accepted17 Aug 2012
Published18 Oct 2012


A new series of N-{4-methyl-5-[4-(4-oxo-2-phenyl(1,3-thiazolidin-3-yl)]-5-sulfanyl(1,2,4-triazol-3-yl)-1,3-thiazol-2-yl }acetamide (7a-l) was synthesized in order to determine their antimicrobial activity and feasible structure–activity relationships. The compounds were synthesized in good yield and the structures of all newly synthesized compounds were established on the basis of their IR, 1HNMR, and elemental analysis. The synthesized compounds were tested in vitro antibacterial activity against Staphylococcus aureus, Escherichia coli, Pseudomonas aeruginosa and Salmonella typhi and antifungal activity against Aspergillus niger, Candida albicans by measuring the zone of inhibition in mm.

1. Introduction

Heterocycles bearing nitrogen, sulphur, and thiazole moieties constitute the core structure of a number of biologically interesting compounds. Literature survey shows that thiazole derivatives play a very important role in biological fields such as antimicrobial [14], antidiabetic [5], antiviral [6], anti-inflammatory [7], antituberculosis [8], and anticancer [9] activities. 1,2,4-Triazole is among the various heterocycles that have received the most attention during the last two decades as potential antimicrobial agents [1013]. Schiff base has good antimicrobial [14], and antifungal [15] activity, and it can be prepared by the acid-catalysed reaction of aldehyde or ketone and amines [16]. Thiazolidin-4-one [17] derivatives are known to exhibit diverse bioactivities such as antidiarrheal [18], anticonvulsant [19], antimicrobial [2022], antidiabetic [23], antihistaminic [24], anticancer [25, 26], anti-HIV [27], cyclooxygenase inhibitory [28], antiplatelet activating factor [2931]. Hence, it is thought of interest to accommodate thiazolidin-4-one and 2-amino benzothiazole moieties in single molecular framework and screen them for their antimicrobial activity. Today, the trend in antimicrobial drug design [32] is to clubbing two or three heterocyclic molecules having different sites or mechanisms of action, and this initiated our construction of compounds containing thiazole, triazole, and thiazolidin-4-one ring systems in the same matrix to serve as a new scaffold towards the development of novel antimicrobial agents. In view of these data, we aimed the synthesis of thiazolyltriazole-substituted thiazolidin-4-one as antimicrobial agents.

2. Result and Discussion

In this present work, a series of new compounds was synthesized. Thus, starting from the ethyl 2-amino-4-methylthiazole-5-carboxylate 1 was synthesized as per reported procedure [33]. Ethyl 2-acetamido-4-methylthiazole-5-carboxylate (2), N-(5-(hydrazinecarbonyl)-4-methylthiazol-2-yl)acetamide (3), potassium dithiocarbazinate (4), N-(5-(4-amino-5-mercapto-4H-1,2,4-triazol-3-yl)-4-methylthiazol-2-yl)acetamide (5), and N-(5-(4-(benzylideneamino)-5-mercapto-4H-1,2,4-triazol-3-yl)-4-methyl thiazol-2-yl)acetamide (6a–l) were prepared as per reported procedure [34]. The Schiff bases on cyclization with mercapto acetic acid in the presence of anhydrous 1,4-dioxane and triturated with an excess of 10% NaHCO3 solution furnished N-{4-methyl-5-[4-(4-oxo-2-phenyl(1,3-thiazolidin-3-yl)]-5-sulfanyl(1,2,4-triazol-3-yl)-1,3-thiazol-2-yl}acetamide (7a–l) as shown in Scheme 1. The structures of the various synthesized compounds were assigned on the basis of elemental analysis, IR, and 1HNMR spectral data. Spectral and analytical data of the title compounds (7a–l) are shown in Tables 1 and 2. The compounds are evaluated for their antimicrobial activity, and results are summaries in Table 3. From the antimicrobial screening, it was observed that all the compounds exhibited activity against all the organisms employed. Looking at the structure activity relationship, marked inhibition in bacteria was observed in the compounds bearing R = H–, 4-Cl–, 2-OH–, 4-OH–, 4-(CH3)2N–, 4-CH3(7a, 7b, 7c, 7f, 7g, 7k) substitutions whereas compound (7d, 7e, 7h, 7i, 7j, 7l) showed moderate to good activity. Fungicidal screening data also revealed that compounds bearing R = H–, 4-Cl–, 4-(CH3)2N–, 3,4,5-(OCH3)3–, 4-Br–, 4-CH3(7a, 7c, 7g, 7j, 7k) imparted maximum activity to the compounds, where as compounds (7b, 7d, 7e, 7f, 7h, 7i) showed moderate to good activity.

Compound R Molecular formula Mol. wt. Yield (%) MP (°C)Elemental analysis Calcd./(found) IR (KBr, cm−1)

7a–HC17H15N6O2S34327296–9847.21 (47.14)3.73 (3.80)19.43 (19.38)3334 (NH), 2465 (S–H), 1742, 1728 (both C=O), 1620 (C=N str.), 1591 (C=C str.), 1349 (C–N), 688 (C–S–C str.)
45.52 (45.44)3.60 (3.65)18.74 (18.82)3292 (Ph–OH Str.), 3234 (NH), 2460 (S–H), 1720, 1700 (both C=O), 1628 (C=N str.), 1598 (C=C str.), 1351 (C–N), 689 (C–S–C str.)
43.72 (43.67)3.24 (3.28)18.00 (18.07)3290 (NH), 2458 (S–H), 1720, 1695 (both C=O), 1622 (C=N), 1600 (C=C str.), 1350 (C–N), 760 (C–Cl), 690 (C–S–C str.)
42.76 (42.71)3.17 (3.22)20.53 (20.57)3360 (NH), 2444 (S–H), 1700, 1689 (both C=O), 1610 (C=N str.), 1523 (–NO2 str), 1352 (C–N), 709 (C–S–C str.).
42.76 (42.68)3.17 (3.15)20.53 (20.60)3172 (NH), 2527 (S–H), 1740, 1700 (both C=O str.), 1610 (C=N str.), 1588 (C=C str.), 1520 (–NO2 str.), 1349 (C–N), 704 (C–S–C str.)
45.52 (45.42)3.60 (3.66)18.74 (18.78)3295 (Ph–OH Str.), 3199 (NH), 2435 (S–H), 1738, 1709 (both C=O), 1636 (C=N str.), 1585 (C=C str.), 1350 (C–N), 672 (C–S–C str.)
47.98 (47.94)4.45 (4.54)20.61 (20.65)3380–3290 (bs, NH), 2460 (S–H), 1720, 1680 (both C=O), 1610 (C=N), 1588 (C=C str.), 1335 (C–N), 692 (C–S–C str.).
45.96 (45.92)4.24 (4.29)16.08 (16.13)3272 (NH), 2394 (S–H), 1718–1673 (both C=O), 1646 (C=N str.), 1588 (C=C str.), 1351 (C–N), 1150 (C–O–C), 689 (C–S–C str.)
46.74 (46.70)3.92 (3.96)18.17 (18.21)3370–3250 (bs, NH), 2403 (S–H), 1715, 1690 (both C=O), 1620 (C=N), 1585 (C=C str.), 1340 (C–N), 1145 (C–O–C), 680 (C–S–C str.)
39.93 (39.89)2.96 (3.00)16.43 (16.48)3175 (NH), 2366 (S–H), 1738, 1690 (both C=O str.), 1605 (C=N str.), 1578 (C=C str.), 1518 (–NO2 str.), 1349 (C–N), 701 (C–S–C str.). 512 (C–Br),
48.41 (48.36)4.06 (4.10)18.82 (18.86)3395–3260 (bs, NH), 2400 (S–H), 1715–1695 (both C=O), 1610 (C=N), 1581 (C=C str.), 1348 (C–N), 695 (C–S–C str.)
45.32 (45.27)3.36 (3.41)18.65 (18.69)3385–3280 (bs, NH), 2430 (S–H), 1725–1695 (both C=O), 1618 (C=N), 1588 (C=C str.), 1348 (C–N), 1235 (C–F), 688 (C–S–C str.)

Compound 1HNMR (DMSO-d6, ppm)

7aδ 2.0 (s, 3H, CH3), 2.45 (s, 3H, CH3), 3.8 (s, 2H, CH2, thizolidin-4-one), 6.02 (s, 1H, CH, thizolidin-4-one), 7.0–7.28 (m, 5H, ArH), 9.2 (s, 1H, NH), 13.87 (br s, 1H, SH)
7bδ 2.1 (s, 3H, CH3), 2.35 (s, 3H, CH3), 3.95 (s, 2H, CH2, thizolidin-4-one), 5.35 (s, 1H, OH), 5.96 (s, 1H, CH, thizolidin-4-one), 6.8–7.2 (m, 4H, ArH), 9.1 (s, 1H, NH), 13.79 (br s, 1H, SH)
7cδ 2.04 (s, 3H, CH3), 2.3 (s, 3H, CH3), 3.92 (s, 2H, CH2, thizolidin-4-one), 5.89 (s, 1H, CH, Thizolidin-4-one), 7.08–7.42 (m, 4H, ArH), 9.15 (s, 1H, NH), 13.89 (br s, 1H, SH)
7dδ 2.01 (s, 3H, CH3), 2.48 (s, 3H, CH3), 3.8 (s, 2H, CH2, thizolidin-4-one), 5.98 (s, 1H, CH, thizolidin-4-one), 7.59–8.15 (m, 4H, ArH), 9.05 (s, 1H, NH), 12.98 (br s, 1H, SH)
7gδ 2.07 (s, 3H, CH3), 2.54 (s, 3H, CH3), 3.06 (s, 6H, CH3), 3.91 (s, 2H, CH2, thizolidin-4-one), 5.85 (s, 1H, CH, thizolidin-4-one), 6.64 (s, 2H, ArH,  Hz), 7.05 (s, 2H, ArH, J = 7.5 Hz), 9.25 (s, 1H, NH), 13.88 (br s, 1H, SH)
7hδ 2.03 (s, 3H, CH3), 2.45 (s, 3H, CH3), 3.83 (s, 9H, OCH3), 3.97 (s, 2H, CH2, thizolidin-4-one), 5.95 (s, 1H, CH, thizolidin-4-one), 7.07 (s, 2H, ArH, J = 1.5 Hz), 9.25 (s, 1H, NH), 13.78 (br s, 1H, SH)
7jδ 2.08 (s, 3H, CH3), 2.5 (s, 3H, CH3), 3.82 (s, 2H, CH2, thizolidin-4-one), 6.01 (s, 1H, CH, thizolidin-4-one), 7.08–7.85 (m, 4H, ArH), 9.35 (s, 1H, NH), 13.82 (br s, 1H, SH)
7kδ 2.11 (s, 3H, CH3), 2.35 (s, 3H, CH3), 2.98 (s, 3H, CH3), 3.76 (s, 2H, CH2, thizolidin-4-one), 6.11 (s, 1H, CH, thizolidin-4-one), 7.05–7.18 (m, 4H, ArH), 9.45 (s, 1H, NH), 13.58 (br s, 1H, SH)

Compound RAntibacterialaAntifungala

7aH–18262022 1926
7b2-OH–16111514 1410
7c4-Cl–12221020 2424
7f4-OH–14251722 1823
7i4-OCH308121011 0913
7j4-Br–11241219 2228
7k4-CH320272125 2025
7l4-F–13151319 1216

aZone of inhibition is measured in mm.
S.a.: Staphylococcus aureus, E.c.: Escherichia coli, P.a.: Pseudomonas aeruginosa, S.t.: Salmonella typhi, A.n.: Aspergillus niger, C.a.: Candida albicans.

3. Experimental Section

The melting points were recorded on electrothermal apparatus and are uncorrected. IR spectra were recorded in KBr on a Perkin-Elmer model-983. 1HNMR spectrum was recorded on Varian Mercury 300 MHz instrument using DMSO- as solvent (chemical shift in δ ppm), using TMS as internal standard. Elemental analysis was performed on a Heracus CHN analyzer. Analyses indicated by the symbols of the elements of functions were within ±/0.4% of the theoretical values.

Synthesis of N-{4-methyl-5-[4-(4-oxo-2-phenyl(1,3-thiazolidin-3-yl)]-5-sulfanyl(1,2,4-triazol-3-yl)-1,3-thiazol-2-yl}acetamide (7a). The compound 6a (0.01 mole) was refluxed with mercapto acetic acid (0.015 mole, 1.38 gm) in the presence of anhydrous 1,4-dioxane (25 mL) at 120°C for 10–12 hrs. The reaction mixture was then cooled and triturated with an excess of 10% NaHCO3 solution. The precipitate was formed; filtered, washed several times with water, and recrystallised in DMSO. Other thiazolidin-4-ones (7b–l) were obtained in similar manner.

4. Antimicrobial Activity

The synthesized compounds (7a–l) were screened for their in vitro antibacterial activity against Staphylococcus aureus, Escherichia coli, Pseudomonas aeruginosa, and Salmonella typhi and antifungal activity against Aspergillus niger, and Candida albicans by measuring the zone of inhibition in mm. The antimicrobial activity was performed by cup plate method [3538] at concentration 100 μg/mL in DMSO and reported in Table 3 for antibacterial and antifungal activities. Nutrient agar was employed as culture medium, and DMSO was used as solvent control for antimicrobial activity. Penicillin and griseofulvin were used as standard for antibacterial and antifungal activities, respectively.

5. Conclusion

In continuation of our previous studies to find new agents against microbial infection, a series of N-{4-methyl-5-[4-(4-oxo-2-phenyl(1,3-thiazolidin-3-yl)]-5-sulfanyl(1,2,4-triazol-3-yl)-1,3-thiazol-2-yl}acetamide (7a–l)was synthesized and its antimicrobial activity was determined. The adopted method is simple, inexpensive, gave good yields. As we consider all results obtained from antibacterial and antifungal tests together we can say that entire compounds tested are active towards bacteria and fungi.


The authors express their sincere thanks to Ms. D. S. Ghorpade, Government College of Pharmacy, Amravati, for the biological activity data, and Head, SAIF, University of Pune, Pune for providing elemental, spectral data.


  1. A. Andreani, M. Granaiola, A. Leoni, A. Locatelli, R. Morigi, and M. Rambaldi, “Synthesis and antitubercular activity of imidazo[2,1-b]thiazoles,” European Journal of Medicinal Chemistry, vol. 36, no. 9, pp. 743–746, 2001. View at: Publisher Site | Google Scholar
  2. J. Clough, S. Chen, E. M. Gordon et al., “Combinatorial modification of natural products: synthesis and in vitro analysis of derivatives of thiazole peptide antibiotic GE2270 A: a-ring modifications,” Bioorganic and Medicinal Chemistry Letters, vol. 13, no. 20, pp. 3409–3414, 2003. View at: Publisher Site | Google Scholar
  3. S.N. Pandeya, D. Sriram, G. Nath, and E. Declercq, “Synthesis, antibacterial, antifungal and anti-HIV activities of Schiff and Mannich bases derived from isatin derivatives and N-[4-(4'-chlorophenyl)thiazol-2-yl] thiosemicarbazide,” European Journal of Pharmaceutical Sciences, vol. 9, no. 1, pp. 25–31, 1999. View at: Publisher Site | Google Scholar
  4. B. Baviskar, S. Patel, B. A. Baviskar, S. S. Khadabadi, and M. R. Shiradkar, “Design and synthesis of some novel chalcones as potent antimicrobial agent,” Asian Journal of Research in Chemistry, vol. 1, no. 2, pp. 67–69, 2008. View at: Google Scholar
  5. A. H. M. Raemakers, F. T. N. Alleuigin, J. Vandenherk, P. J. A. Domoen, T. T. T. Ottenwert, and P. A. J. Janssen, “Novel broad-spectrum anthelmintics. Tetramisole and related derivatives of 6-arylimidazo[2,1-b]thiazole,” Journal of Medicinal Chemistry, vol. 54, no. 4, pp. 545–551, 1966. View at: Publisher Site | Google Scholar
  6. S. K. Sharma, M. Tandeon, and J. W. Lown, “Design and synthesis of novel thiazole-containing cross-linked polyamides related to the antiviral antibiotic distamycin,” Journal of Organic Chemistry, vol. 65, no. 4, pp. 1102–1107, 2000. View at: Publisher Site | Google Scholar
  7. P. K. Sharma, S. N. Sawhney, A. Gupta, G. B. Singh, and S. Bani, “Synthesis and antiinflammatory activity of some 3-(2-thiazolyl)-1,2-benzisothiazoles,” Indian Journal of Chemistry B, vol. 37, p. 376, 1998. View at: Google Scholar
  8. M. R. Shiradkar, K. K. Murahari, H. R. Gangadasu et al., “Synthesis of new S-derivatives of clubbed triazolyl thiazole as anti-Mycobacterium tuberculosis agents,” Bioorganic and Medicinal Chemistry, vol. 15, no. 12, pp. 3997–4008, 2007. View at: Publisher Site | Google Scholar
  9. E. M. Hodnett and W. J. Dunn, “Structure-antitumor activity correlation of some Schiff bases,” Journal of Medicinal Chemistry, vol. 13, no. 4, pp. 768–770, 1970. View at: Publisher Site | Google Scholar
  10. S. Narayanaswami and K. Richardson, European Patent, 1983, 96, 569 A1.
  11. M. B. Gravestock and M. Barry, European Patent, 1984, EP 94, 146B1.
  12. B. Hirsch, D. Lohmann, G. Menzel, G. Schuster, and E. Stenz, German Democratic Republic Patent, 1983, DD2, 34, 003.
  13. T. Ikeda and K. Tada, European Patent, 1988, EP 2,62,589 B1.
  14. B. D. Naik and K. R. Desai, “Synthesis of some heterocyclic Schiff base and azetidinone compounds and their antibacterial activity,” Asian Journal of Chemistry, vol. 16, no. 3-4, pp. 1749–1752, 2004. View at: Google Scholar
  15. D. U. Warad, C. D. Satish, V. H. Kulkarni, and C. S. Bajgur, “Synthesis, structure and reactivity of zircordum(IV), vanadium(IV), cobalt(II), nickel(II) and copper(II) complexes derived from carbohydrazide schiff base ligands,” Indian Journal of Chemistry A, vol. 39, no. 4, pp. 415–420, 2000. View at: Google Scholar
  16. S. Desai, P. B. Desai, and K. R. Desai, “Synthesis of new heterocyclic thiazolidinone and azetidinone compounds and their anticancer activity,” Heterocyclic Communications, vol. 5, no. 4, pp. 385–387, 1999. View at: Google Scholar
  17. R. B. Lesyk and B. S. Zimenkovsky, “4-Thiazolidones: centenarian history, current status and perspectives for modern organic and medicinal chemistry,” Current Organic Chemistry, vol. 8, no. 16, pp. 1547–1577, 2004. View at: Publisher Site | Google Scholar
  18. M. V. Diurno, O. Mazzoni, F. Capasso, A. A. Izzo, and A. Bolognese, “Synthesis and pharmacological activity of 2-(substituted phenyl)-3{2 or 3-[(4-substituted phenyl-4-hydroxy)piperidino]ethyl or propyl}-1,3- thiazolidin-4-ones,” Farmaco, vol. 52, no. 4, pp. 237–241, 1997. View at: Google Scholar
  19. N. Ergenc and G. Capan, “Synthesis and anticonvulsant activity of new 4-thiazolidone and 4- thiazoline derivatives,” Farmaco, vol. 49, no. 6, pp. 449–451, 1994. View at: Google Scholar
  20. S. Desai, R. Desai, and N. Chandra Desai, “Vitamin A intervention in the Thar Desert,” Indian Journal of Ophthalmology, vol. 51, no. 4, pp. 361–363, 2003. View at: Google Scholar
  21. R. C. Sharma and D. Kumar, “Synthesis of some new thiazolidin-4-ones as possible antimicrobial agents,” Journal of Indian Chemical Society, vol. 77, no. 10, pp. 492–493, 2000. View at: Google Scholar
  22. E. Piscapo, M. V. Diurno, R. Gagliardi, and O. Mazzoni, “Studies on heterocyclic compounds: 1,3-thiazolidin-4-one derivatives. IV. Biological activity of variously substituted 2,3-diaryl-1,3-thiazolidin-4-ones,” Bollettino Della Societa Italiana di Biologia Sperimentale, vol. 65, no. 9, pp. 853–859, 1989. View at: Google Scholar
  23. H. Ueno, T. Oe, I. Snehiro, and S. Nakamura, “US Patent, 5594116, 1997,” Chemical Abstracts, vol. 126, 157507 pages, 1977. View at: Google Scholar
  24. T. Previtera, M. G. Vigorita, M. Bisila, F. Orsini, F. Benetolla, and G. Bombieri, “3,3'-Di [1,3-thiazolidine-4-one] system. VI. Structural and conformational studies on configurational isomers with antihistaminic activity,” European Journal of Medicinal Chemistry, vol. 29, no. 4, pp. 317–324, 1994. View at: Publisher Site | Google Scholar
  25. M. V. Diurno, O. Mazzoni, G. Correale et al., “Synthesis and structure-activity relationships of 2-(substituted phenyl)-3-[3-(N,N-dimethylamino)propyl]-1,3-thiazolidin-4-ones acting as H1-histamine antagonists,” Farmaco, vol. 54, no. 9, pp. 579–583, 1999. View at: Publisher Site | Google Scholar
  26. M. Y. Ebeid, O. A. Fathallah, M. I. El-Zaher, M. M. Kamel, W. A. Abdon, and M. M. Anwar, “New tetralyl thiazoles the anti- HIV and anticancer screening of 3-4-[6(1,2,3,4-tetrahydronaphthyl)-thiazol-2-yl-2-(p-chlorophenyl)-thiazolidin-4-one,” Bulletin of Faculty of Pharmacy, vol. 34, p. 125, 1996. View at: Google Scholar
  27. R. K. Rawal, Y. S. Prabhakar, S. B. Katti, and E. De Clercq, “2-(Aryl)-3-furan-2-ylmethyl-thiazolidin-4-ones as selective HIV-RT Inhibitors,” Bioorganic and Medicinal Chemistry, vol. 13, no. 24, pp. 6771–6776, 2005. View at: Publisher Site | Google Scholar
  28. R. Ottaná, E. Mazzon, L. Dugo et al., “Modeling and biological evaluation of 3,3′-(1,2-ethanediyl)bis[2-(4-methoxyphenyl)-thiazolidin-4-one], a new synthetic cyclooxygenase-2 inhibitor,” European Journal of Pharmacology, vol. 448, no. 1, pp. 71–80, 2002. View at: Publisher Site | Google Scholar
  29. H. Koike, N. Imanashi, Y. Natsume, and S. Morooka, “Effects of platelet activating factor receptor antagonists on intracellular platelet activating factor function in neutrophils,” European Journal of Pharmacology, vol. 269, no. 3, pp. 299–309, 1994. View at: Publisher Site | Google Scholar
  30. Y. Tanabe, H. Yamamoto, M. Murakami et al., “Synthetic study of the highly potent and selective anti-platelet activating factor thiazolidin-4-one agents and related compounds,” Journal of the Chemical Society, no. 7, pp. 935–947, 1995. View at: Google Scholar
  31. Y. Tanabe, G. Suzukamo, Y. Komuro et al., “Structure-activity relationship of optically active 2-(3-pyridyl)thiazolidin-4-ones as a PAF antagonist,” Tetrahedron Letters, vol. 32, no. 3, pp. 379–382, 1991. View at: Publisher Site | Google Scholar
  32. M. R. Shiradkar, P. Unnat, A. K. Chakravarthy, A. Maheta, and V. S. K. Gorentla, “Microwave assisted synthesis and antimicrobial screening of fused triazoles,” ARKIVOC, vol. 14, pp. 141–154, 2006. View at: Google Scholar
  33. R. M. Dodson and L. C. King, “The reaction of ketones with halogens and thiourea,” Journal of the American Chemical Society, vol. 67, p. 2242, 1945. View at: Google Scholar
  34. B. A. Baviskar, M. R. Shiradkar, S. S. Khadabadi, S. L. Deore, and K. G. Bothara, “Synthesis of thiazolyltriazole subtituted azetidiones as antinacrobial agents,” Indian Journal of Chemistry B, vol. 50B, pp. 321–325, 2011. View at: Google Scholar
  35. M. Shiradkar, R. Kale, B. Baviskar, and R. Dighe, “Microwave assisted synthesis and antimicrobial screening of pyrazoline-5-ones,” Asian Journal of Chemistry, vol. 19, no. 1, pp. 449–453, 2007. View at: Google Scholar
  36. B. A. Baviskar, B. Baviskar, S. Chuadhary et al., “Synthesis of novel benzimidazole derivatives as potent antimicrobial agent,” RASAYAN Journal of Chemistry, vol. 2, no. 1, pp. 186–190, 2009. View at: Google Scholar
  37. Indian Pharmacopoeia, Ministry of Health and Family Welfare, New Delhi, 1996, A-114.
  38. B. A. Baviskar, B. Baviskar, M. R. Shiradkarm, U. A. Deokate, and S. S. Khadabadi, “Synthesis and antimicrobial activity of some novel benzimidazolyl chalcones,” E-Journal of Chemistry, vol. 6, no. 1, pp. 196–200, 2009. View at: Google Scholar

Copyright © 2013 B. A. Baviskar et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

More related articles

 PDF Download Citation Citation
 Download other formatsMore
 Order printed copiesOrder

Related articles

We are committed to sharing findings related to COVID-19 as quickly as possible. We will be providing unlimited waivers of publication charges for accepted research articles as well as case reports and case series related to COVID-19. Review articles are excluded from this waiver policy. Sign up here as a reviewer to help fast-track new submissions.